N/A
N=1,389
PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders
Rheumatic Diseases · Arthralgia · Myalgias/Myopathy · Lumbago
Bottom Line
View on ClinicalTrials.gov: NCT00922428 ↗Enrolled (actual)
1,389
Serious AEs
0.0%
Results posted
May 2015
Primary outcome: Primary: Visual Analog Scale (VAS) — 6.57; 4.23; 2.61 units on a scale
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
- Primary completion
- May 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Analog Scale (VAS) |
6.57; 4.23; 2.61 | — |
| PRIMARY Tolerability of the Drug |
2.8; 97.2 | — |
| PRIMARY Pain at Rest |
57.5; 76.8; 44.1 | — |
| PRIMARY Pain in Movement |
67.5; 80.8; 50.1 | — |
| PRIMARY Pain After Rest |
60.2; 78.6; 49.8 | — |
| PRIMARY Pain on Weight-bearing |
64.1; 79.1; 50.4 | — |
| PRIMARY Morning Stiffness |
54.4; 74.5; 42.9 | — |
| PRIMARY Tenderness |
64.5; 80.8; 50.3 | — |
| PRIMARY Antalgic Position |
61.3; 79.4; 43.4 | — |
| SECONDARY Acceptance of the Drug |
90.5; 8.7 | — |
Summary
The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders.
Eligibility Criteria
Due to the design as an Observational Study no inclusion or exclusion criteria for therapy are named. The included patient group is described under "Cohort / Group".
Observational Criteria (=inclusion criteria for documentation):
- Males and females
- At least 18 years old
- Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc.
Exclusion criteria for documentation:
- younger than 18 years
- no Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc.
- no treatment with PASCOE-Agil HOM-Injektopas
Data sourced from ClinicalTrials.gov (NCT00922428). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.